JPY 982.0
(-1.01%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -697.43 Million JPY | -64.07% |
2022 | -425.08 Million JPY | -702.37% |
2021 | 70.56 Million JPY | 118.96% |
2020 | -372.13 Million JPY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -219.01 Million JPY | 4.75% |
2024 Q1 | -229.94 Million JPY | -35.88% |
2023 Q4 | -169.23 Million JPY | -2.85% |
2023 FY | -697.43 Million JPY | -64.07% |
2023 Q3 | -164.54 Million JPY | 14.08% |
2023 Q2 | -191.51 Million JPY | -11.26% |
2023 Q1 | -172.13 Million JPY | 2.14% |
2022 FY | -425.08 Million JPY | -702.37% |
2022 Q4 | -175.9 Million JPY | -15.57% |
2022 Q3 | -152.21 Million JPY | 0.0% |
2021 FY | 70.56 Million JPY | 118.96% |
2020 FY | -372.13 Million JPY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 113.64% |
Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 100.326% |
Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.803% |
Shionogi & Co., Ltd. | 171.46 Billion JPY | 100.407% |
Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -256.725% |
Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 102.222% |
Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 107.331% |
Eisai Co., Ltd. | 53.4 Billion JPY | 101.306% |
Morishita Jintan Co., Ltd. | 716 Million JPY | 197.407% |
Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 105.297% |
Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 112.019% |
Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 135.511% |
Nippon Chemiphar Co., Ltd. | -494 Million JPY | -41.182% |
Tsumura & Co. | 20.01 Billion JPY | 103.484% |
Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 117.362% |
Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 113.849% |
Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 103.952% |
Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 118.078% |
Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 107.178% |
KYORIN Holdings, Inc. | 6.01 Billion JPY | 111.599% |
Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 77.349% |
Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 117.911% |
SymBio Pharmaceuticals Limited | -811.66 Million JPY | 14.074% |
MedRx Co., Ltd | -933 Million JPY | 25.248% |
Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 113.537% |
Solasia Pharma K.K. | -1.13 Billion JPY | 38.768% |
Modalis Therapeutics Corporation | -2.37 Billion JPY | 70.572% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 110.73% |
Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 103.693% |
Toho Holdings Co., Ltd. | 19.33 Billion JPY | 103.608% |
Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 115.915% |